Share

February 2022; 12 (1) Research

Association Between Pharmacy Benefit Restrictions and Disease-Modifying Therapy Use in the Medicare Part D Program

Daniel M. Hartung, Kirbee A. Johnston, Jessina C. McGregor, Dennis N. Bourdette
First published July 27, 2021, DOI: https://doi.org/10.1212/CPJ.0000000000001118
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
39

Share

Article Information

vol. 12 no. 1 36-42
DOI: 
https://doi.org/10.1212/CPJ.0000000000001118
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received September 29, 2020
  • Accepted June 23, 2021
  • First Published July 27, 2021.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Daniel M. Hartung, PharmD, MPH,
    2. Kirbee A. Johnston, MPH (kirbee.a.johnston{at}gmail.com),
    3. Jessina C. McGregor, PhD (mcgregoj{at}ohsu.edu) and
    4. Dennis N. Bourdette, MD (bourdett{at}ohsu.edu)
  1. Daniel M. Hartung, PharmD, MPH,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) PCORI Peer Review Process, Associate Editor, 2016 - present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. National Multiple Sclerosis Society

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH/NIDA, UG1DA015815, co-I, 2018 - 2019 (2) NIH/NIDA, R01DA045745, co-I, 2018 - 2022 (3) NIH/NIDA, 1R01DA044284, co-I, 2018 - 2023 (4) NIH/NIDA, R01DA046468, co-I, 2018 - 2023 (5) CDC, R01CE003008, co-I, 2018 - 2021 (6) AHRQ, 1R21HS028119-01, PI 2021 - 2023

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Kirbee A. Johnston, MPH (kirbee.a.johnston{at}gmail.com),
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Jessina C. McGregor, PhD (mcgregoj{at}ohsu.edu) and
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Infection Control & Hospital Epidemiology Statistical Consultant, 2015-present JAMA Network Open Methodology/Statistical Consultant, 2018-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. AHRQ 1R03HS026819-A1 Evaluating Antibiotic Utilization Metrics PI 9/01/2019-8/31/2021 AHRQ 1R01HS02517701A1 Dental Prescribing of Antibiotics and Opioids: High Use in the Absence of Evidence Co-I/Site PI 09/30/17-01/07/22 VA HSR&D IIR 17-039 Improving Veteran Health by Increasing Dental Stewardship of Antibiotics and Opioids Co-I 07/01/18-06/30/22 AHRQ 1R01HS026747-01 Optimizing Antibiotic Prescribing on Discharge to Long-Term Care Facilities Co-I 4/1/2019 – 1/31/2022 CDC 6 NU50CK000541-01-05 Oregon 2019 Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) Site PI 8/1/2019-9/1/2020

    Research Support, Academic Entities:

    1. Oregon Health & Science University-Portland State University School of Public Health

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Dennis N. Bourdette, MD (bourdett{at}ohsu.edu)
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Neurology, Member Editorial Board, 2013-present

    Patents:

    1. (1) Use patent for the treatment of multiple sclerosis with cyclic peptide derivatives of cyclosporin (2) Patent pending for thyromimetic drugs for stimulating remyelination in multiple sclerosis.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) I provide consultations to Magellan Health on individual cases regarding requests to insurance companies for coverage of expensive therapies (2) I provide patient consultations for Best Doctors, Inc.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Autobahn Therapeutics

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. College of Pharmacy (DMH, KAJ, JCM), Oregon State University; and Department of Neurology (DNB), Oregon Health & Science University, Portland.
  1. Correspondence
    Dr. Hartung hartungd{at}ohsu.edu
View Full Text

Article usage

Article usage: July 2021 to December 2022

AbstractFullPdfSource
Jul 20219002Highwire
Aug 202141203Highwire
Sep 20215001Highwire
Oct 20213902Highwire
Nov 20213103Highwire
Dec 20212200Highwire
Jan 20221701Highwire
Feb 2022286135Highwire
Mar 202218755Highwire
Apr 20225925Highwire
May 20222013Highwire
Jun 20221343Highwire
Jul 20221403Highwire
Aug 20222440Highwire
Sep 20226030Highwire
Oct 20228252Highwire
Nov 20229911Highwire
Dec 20225700Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me